MNTA Momenta Pharmaceuticals, Inc.

13.380.06 (+0.45%)
Close: September 20, 2019

Quote

Previous Close
$13.38
Day Range
$13.21-$13.67
52 Week Range
$9.51-$28.15
Volume
1,263,670
Avg Volume
474,387
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$1.32B
Enterprise Value (EV)
$898.29M
PE Ratio
-
EV/EBITDA
-5.89
Price/Sales
-
Price/Book
2.86
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
-$152.45M
EPS, ttm
-$2.36
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
11/4/2019 (43 days)
Debt to Equity
-
Debt
-
Cash
$422.41M
Net Debt
-

Performance

Beta
1.25
200 Day Moving Avg
$12.57
50 Day Moving Avg
$11.94
52 Week Change
-50.26%
YTD Change
18.86%
1 Month Change
8.69%
3 Month Change
9.31%
6 Month Change
-5.11%
1 Year Change
-50.26%
2 Year Change
-3.23%
5 Year Change
39.53%

Share Count

Shares Outstanding
98.7M
Float
97.7M
Restricted Shares
1.0M
Restricted Shares, %
1.03%

Momenta Pharmaceuticals, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Craig A. Wheeler

Website: http://www.momentapharma.com

Description: Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.

Employees: 131